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Review
A One Health Approach to Hypertrophic 
Cardiomyopathy
Yu Ueda, DVMa and Joshua A. Stern, DVM, PhDa,b,*
aDepartment of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA; 
bCalifornia National Primate Research Center, University of California-Davis, Davis, CA
Hypertrophic cardiomyopathy (HCM†) is the most common inherited cardiac disease in humans and 
results in significant morbidity and mortality. Research over the past 25 years has contributed enormous 
insight into this inherited disease particularly in the areas of genetics, molecular mechanisms, and 
pathophysiology. Our understanding continues to be limited by the heterogeneity of clinical presentations 
with various genetic mutations associated with HCM. Transgenic mouse models have been utilized 
especially studying the genotypic and phenotypic interactions. However, mice possess intrinsic cardiac 
and hemodynamic differences compared to humans and have limitations preventing their direct 
translation. Other animal models of HCM have been studied or generated in part to overcome these 
limitations. HCM in cats shows strikingly similar molecular, histopathological, and genetic similarities 
to human HCM, and offers an important translational opportunity for the study of this disease. Recently, 
inherited left ventricular hypertrophy in rhesus macaques was identified and collaborative investigations 
have been conducted to begin to develop a non-human primate HCM model. These naturally-occurring 
large-animal models may aid in advancing our understanding of HCM and developing novel therapeutic 
approaches to this disease. This review will highlight the features of HCM in humans and the relevant 
available and developing animal models of this condition.
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) has been rec-
ognized for more than fifty years, with first pathologi-
cal description published in 1958, followed by the first 
clinical report in the early 1960s [1]. Since then, clinical, 
biochemical, pathologic, and genetic studies have made 
enormous progress to better understand this inherited dis-
ease. However, this information has not yet been trans-
lated into practical information necessary for the preven-
tion or treatment of HCM. This is in part because of the 
unexpected heterogeneity and complexity in phenotypic 
presentations with underlying genetic causes of HCM. 
To date, over 1,500 mutations in at least 20 genes en-
coding the myofilaments of the sarcomere or Z-disc have 
been identified to be causative or associated with HCM. 
This polygenetic feature of HCM makes a homogenous 
study population challenging to identify given the large 
numbers required for successful human clinical trials [2]. 
Controlled prospective studies are necessary to identify 
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pre-clinical signs of disease in human HCM patients, 
but such studies are complicated, expensive, and require 
lengthy periods of longitudinal follow-up. Mouse models 
of HCM overcome some of these challenges to advance 
our understanding of HCM. However, they have other 
limitations that prevent direct translation to human medi-
cine because of intrinsic differences in their cardiac phys-
iology, response to cardiac stress, hemodynamics, and the 
inherent resistance of rodent hearts to arrhythmia due in 
part to the small size and rapid kinetics of their hearts. 
The need for more direct translational models, particu-
larly large-animal models, of HCM is clearly identified.
HCM is also known to be the most common inher-
ited cardiac disease in the domestic cats [3]. Large num-
bers of biochemical, genetic, and clinical studies have 
been conducted evaluating feline HCM over the last few 
decades. These studies revealed that feline HCM follows 
incredibly similar clinical and pathological presentations 
as human HCM, and shows promise to serve as an ani-
mal model of human HCM. At least two cat breeds share 
genetic similarity to human HCM cases where mutations 
in myosin binding protein C (MYBPC) have been re-
ported as a major contributor to development of HCM 
[4,5]. However, a majority of feline HCM cases are of 
yet unknown genetic etiology and other undiscovered 
mutations are likely involved in developing feline HCM. 
Recently a unique large animal model of HCM is ob-
served in the rhesus macaque, and pedigree investigation 
has revealed that this condition is also familial and likely 
heritable [6,7]. Once clinical, molecular, pathologic, and 
genetic studies are completed, this may serve as an ex-
cellent non-human primate model of HCM and further 
our ability to perform meaningful research into various 
aspects of HCM including novel therapeutics. 
In this review, current knowledge and understanding 
of pathophysiological, clinical, diagnostic, and genetic 
aspects of human HCM are reviewed. Furthermore, trans-
lational and comparative models of naturally occurring or 
transgenic HCM in other species such rodents, cats, and 
non-human primates are summarized and discussed to 
identify the potentials for propelling further translational 
investigations of HCM.
GENERAL PATHOPHYSIOLOGY OF 
HYPERTROPHIC CARDIOMYOPATHY
Hypertrophied myocytes with disorganized sarco-
meric alignment are hallmark histopathological changes 
in human HCM (Figure 1) [8]. The hypertrophied myo-
cytes may possess unusually shaped nuclei and chaotic 
myofibril alignment [8]. They also frequently have abnor-
malities in the coronary arteriolar walls [9], elongation or 
malformation of mitral valve leaflets [10], and presence 
of myocardial fibrosis, leading to further functional ab-
normalities of the heart [11].
Primary components of the functional disturbances 
observed with HCM are reduced stroke volume with dia-
stolic dysfunction, reduced chamber size, and decreased 
compliance of the left ventricle (LV) [12]. Stroke vol-
ume can be even further reduced by the presence of left 
ventricular outflow obstruction (LVOTO). LVOTO most 
commonly develops secondary to systolic anterior mo-
Figure 1. Gross necropsy images of (A) cat and (B) rhesus macaque with severe left ventricular hypertrophy. Hearts 
were transversely transected midway between the apex and base of the hearts (Gross necropsy image of rhesus 
macaque courtesy of R. Reader). 
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tion (SAM) of the mitral valve generating mechanical 
interference along the pathway of the LV outflow tract. 
This causes increased pressure in the LV lumen and ele-
vated flow velocity through the LV outflow tract. Elevat-
ed LV outflow tract velocity can further worsen SAM and 
lead to the development of mitral regurgitation (Figure 
2). LVOTO can also occur at the mid-cavity or apex of 
the LV lumen resulting from symmetric or asymmetric 
hypertrophy of LV anterior and/or posterior walls [13]. 
Therefore, the degree of reduced stroke volume due to 
HCM may vary depending on the degrees of diastolic 
dysfunction, myocyte hypertrophy, LVOTO, mitral re-
gurgitation and cardiac systolic dysfunction. Additional-
ly, it is important to note that LVOTO may be dynamic 
and often dependent on physiological state, making its 
presence more common and more severe with exercise or 
catecholamine stimulation [14,15].
HYPERTROPHIC CARDIOMYOPATHY IN 
HUMANS
A previous population analysis reported in 1995 es-
timated the prevalence of human HCM to be at least 1 
in 500 adults [2,16]. HCM is identified across all ethnic 
groups as well as in both sexes [17]. The overall prev-
alence of HCM is lower in African-American patients 
compared to white patients, but sudden death due to 
HCM is more frequent in African-Americans in the Unit-
ed States [18,19]. Male patients are overrepresented to fe-
male patients, while female patients tend to be diagnosed 
with HCM at older ages with symptoms of heart failure 
(HF) [18-20]. However, the overall prevalence of HCM 
may be underestimated since many HCM individuals do 
not develop any obvious clinical symptoms during their 
life spans [21]. Asymptomatic HCM is frequently diag-
nosed during family screening for HCM or diagnostic 
examination for other cardiovascular diseases on electro-
cardiography (ECG), echocardiography, or cardiovascu-
lar magnetic resonance images (CMR) [2].
Clinical Manifestations in Humans
HCM is associated with a broad spectrum of clinical 
manifestations from no symptoms with normal lifestyle 
and life span to serious clinical complications [21,22]. 
The common clinical symptoms related to HCM include 
sudden death (SD), heart failure (HF), and atrial fibrilla-
tion (AF). Age is a key factor that impacts the likelihood 
of developing the clinical symptoms, where SD events 
are most common in young patients, while HF and AF are 
more common in middle-aged to elderly patients [23]. In 
fact, HCM remains the most common cause of athletic 
field deaths in high school and college age students in the 
United States [24]. These SD events may occur without 
warning during physical activity, and are thought to be 
primarily due to development of ventricular tachycardia 
and fibrillation [22]. 
The clinical signs of HF in HCM patients include 
difficulty breathing, which is often associated with the 
presence of diastolic dysfunction, LVOTO, mitral regur-
gitation, and systolic dysfunction [21,22]. About one-
third of HCM patients with HF do not have significant 
Figure 2. 2-Dimensional right parasternal left ventricular outflow tract view in systole with color-Doppler showing left 
ventricular outflow tract obstruction secondary to systolic anterior motion of the mitral valve in a cat with HCM. Mitral 
valve regurgitation is also evident.
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HCM cases are primarily associated with mutations in 
two major genes: beta-myosin heavy chain (MYH) and 
myosin-binding protein C (MYBPC) [28]. These proteins 
are the major components of the thick filament of sarco-
meres providing structural support and regulating muscle 
contractions. Notably, HCM patients possessing a muta-
tion in one of these two genes are observed to have in-
creased severity of HCM compared to HCM patients with 
mutations in other genes (Table 1) [30]. Despite these 
advancements in understanding the genetic etiology of 
HCM in many cases, this genetic data has not altered the 
treatments or provided enough information to prognosti-
cate or prevent HCM in a clinical setting. This is mainly 
due to the vast devastating genetic heterogeneity of this 
condition, where various mutations are identified with-
in the MYH and MYBPC genes [29]. For example, some 
sarcomeric mutations in these major genes don’t cause 
significant left ventricular hypertrophy (LVH), but rather 
lead patients to develop other clinical manifestations of 
HCM including diastolic dysfunction, AF, and SD [31]. 
Other studies have shown that different mutations in these 
genes may result in different morphology of LVH [48]. In 
addition, about 3 to 5 percent of HCM affected humans 
have more than one HCM-associated mutation and the 
clinical symptoms in patients with multiple mutations are 
generally more severe and confer greater risk of SD [32].
Genes encoding cardiac troponins (TNNI3, TNNT2, 
LVOTO at rest, but develop LVOTO during exercise or 
under stress [25]. Exercise induced LVOTO identifies pa-
tients possessing higher risk of HF development, and thus 
therapeutic intervention before developing HF symptoms 
may become indicated.
Approximately 25 percent of HCM patients develop 
atrial fibrillation (AF) during their clinical courses and 
thus AF is most commonly identified clinical symptom 
of HCM [26]. Development of AF due to HCM is asso-
ciated with increasing age, greater left atrial size, and 
impaired left atrial ejection fraction [27]. Manifestation 
of AF itself may not result in serious clinical conditions, 
although it is often associated with the presence of LVO-
TO and progressive HF [28]. In addition, AF due to HCM 
is a risk factor for developing thromboembolic disease 
(e.g., stroke). Interestingly, no significant relationship in 
human HCM has been reported between AF and SD [26].
Genetics of HCM in Humans
HCM in humans is an inherited disease with an auto-
somal dominant pattern and incomplete penetrance [29]. 
Since the first sarcomeric gene mutation associated with 
HCM was identified approximately 25 years ago, more 
than 1,500 mutations across at least 20 genes encoding 
myofilament proteins have been identified and linked to 
human HCM [2,29]. Approximately 70 percent of human 
Table 1. Identified genetic mutations in association with HCM in various species.
Species Genes References
Human ACTC1 (Actin, Alpha, Cardiac Muscle 1)
ACTN2 (Actin Alpha 2)
CALR3 (Calreticulin 3)
CSRP3 (Cysteine and Glycine Rich Protein 3)
JPH2 (Junctophilin 2)
MYBPC3 (Myosin Binding Protein C, Cardiac)
MYH7 (Myosin Heavy Chain 7)
MYL2 (Myosin Light Chain 2)
MYL3 (Myosin Light Chain 3)
MYOM1 (Myomesin-1)
MYOZ2 (Myozenin 2)
NEXN (Nexilin F-actin Binding Protein)
PLN (Phospholamban)
PRKAG2 (Protein Kinase AMP-Activated Catalytic Subunit α2)
TCAP (Titin-Cap)
TNNI3 (Troponin I3, Cardiac Type)
TNNT2 (Troponin T2, Cardiac Type)
TPM1 (Tropomyosin 1)
TTN (Titin)
VCL (Vinculin)
[114-116]
[117,118]
[119]
[37,38]
[120,121]
[122-130]
[131-139]
[140-142]
[140,143,144]
[41]
[40,145]
[146]
[147,148]
[149-152]
[39,153]
[34,115,154,155]
[35,100,156-158]
[156,159,160]
[36,161]
[162]
Cat MYBPC3 (Myosin Binding Protein C, Cardiac) [4,5,163]
Pig Not yet defined
Dog Not yet defined
Rhesus macaque Not yet defined Under investigation
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specific to HCM, and further evaluations are necessary 
to rule out other diseases resulting in the similar ECG 
abnormalities (e.g., myocardial infarction).
Imaging plays a key role in diagnosing HCM. The 
two imaging modalities frequently used to diagnose HCM 
in humans include echocardiography and cardiovascular 
magnetic resonance images (CMR). HCM is typically 
diagnosed by two-dimensional (2D) echocardiography 
with LV wall thickness (more than 15 mm in humans) in 
diastole, after excluding other possible causes of LVH, 
such as aortic stenosis, systemic hypertension, infiltrative 
disease, storage disorders, and athlete’s heart (3) [22]. 2D 
echocardiography also identifies the pattern and location 
of LVH. The common locations for LVH described on 2D 
echocardiography include basal anterior septum, anterior 
free wall, and the posterior septum at the mid-LV lev-
el [47]. Two-dimensional echocardiography can be used 
to assess the outflow tract and valves for regurgitations 
or SAM under various conditions such as exercise, Val-
salva maneuver, and isoproterenol administration. Using 
continuous-wave, pulsed-wave, and color-Doppler tech-
niques, echocardiography can determine the LV outflow 
gradients to determine the presence of LVOTO before and 
after these physiologic manipulations. CMR can provide 
additional information about cardiac structure. CMR may 
identify the LVH in segments not visualized well with 
echocardiography and further characterize structural ab-
normalities of the mitral valve or papillary muscles. CMR 
combined with late gadolinium enhancement can also be 
used to quantify myocardial fibrosis which is reported to 
be a predictor of SD [48].
Cardiac biomarkers have been frequently utilized to 
assess the degree and severity of human HCM. Several 
studies showed that elevated serum cTnT level was as-
sociated with degree of LVH and diastolic dysfunction, 
increased risk of developing SD, HF, AF, and thrombo-
embolic disease (e.g., stroke) in HCM patients [49]. cTnI 
is also found to be associated with the degree of LVH 
and diastolic dysfunction due to HCM [50]. In addition, 
the recently developed highly sensitive troponin (hs-Tn) 
assays have significantly higher sensitivity and specific-
ity for diagnosing HCM and elevated hs-Tn level is as-
sociated with a greater risk of developing complications 
such as SD and HF [50]. B-type natriuretic peptide (BNP) 
concentration has also been used for diagnosing and 
prognosticating HF due to HCM, and the degree of LVH 
is also known to be independently associated with BNP 
level [51]. BNP level is significantly elevated in human 
HCM patients with HF. BNP level is shown to trend high-
er as the severity of HF increases [52]. However, there is 
significant overlap of serum BNP concentrations in HCM 
patients with HF and without HF [52]. Therefore, diag-
nosing the presence and degree of HF in patients with 
HCM based just solely on the BNP levels may have lim-
TNNC1) are found to play a key role in developing HCM 
in humans (Table 1). The cardiac troponin is composed 
of three subunits including cardiac troponin C (cTnC), 
cardiac troponin I (cTnI), and cardiac troponin T (cTnT). 
Among these genes, TNNI3 is specific to cTnI and a sin-
gle protein isoform has been identified, while TNNT2 is 
specific to cTnT and twelve different isoforms have been 
described [33]. Previous studies noted that several mis-
sense mutations in TNNI3 and TNNT2 were found to be 
associated with developing varied clinical manifestations 
of HCM in humans. For example, TNNI3 gene mutation 
(R145G missense mutation) is shown to be associated 
with developing significant LVH [34], while TNNT2 gene 
mutation (179N missense mutation) was reported to be 
associated with higher incidence of SD and minimal LVH 
[35].
Genes encoding proteins within the Z-disc and 
M-band are also known to have mutations associated 
with human HCM. These genetic variants were identi-
fied within the genes encoding titin (TTN), muscle LIM 
protein (CSRP), myozenin 2 (MYOZ2) and telethonin 
(TCAP) [36-40]. These mutations in Z-disc result in al-
terations of protein-protein interactions leading to exces-
sive response to mechanical load and ultimately result in 
LVH. Similarly, a mutation in myomesin as an M-band 
protein has been identified in human HCM patients [41]. 
Although many mutations have been reported for 
HCM in humans, the association of specific mutations 
with the clinical characteristics of HCM is still controver-
sial because of genotypic and phenotypic heterogeneities. 
These mutations cannot be routinely used to prognosti-
cate human HCM as large cohorts of a single mutation 
are infrequent and thus comparing clinical outcomes by 
mutation is incredibly challenging [42]. Additionally, the 
presence of modifier genes that can modulate the phe-
notype of HCM, renders genotype-based prognostica-
tion even more challenging. For example, a few genetic 
variants of the angiotensin II type 2 receptor gene were 
described to be associated with the severity of LVH in hu-
man HCM patients with sarcomeric gene mutations [43]. 
Another study evaluated the calmodulin (CALM3) gene 
and reported a mutation that modifies HCM expression 
by altering an intracellular calcium sensitization in hu-
man HCM [44].
Diagnosis of HCM in Humans
Electrocardiographic (ECG) abnormalities are fre-
quently seen, occurring in approximately 95 percent of 
human HCM in one study [45]. Typical ECG findings in 
humans with HCM include increased precordial voltag-
es and ST segment and T wave abnormalities with LVH, 
prominent deep and narrow Q-waves with asymmetric 
LVH, and p-wave abnormalities (P-mitrale) with left atri-
al enlargement [46]. These ECG abnormalities are not 
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compensatory mechanisms showing that this mutation 
caused higher energy to create a contraction force and re-
duced diastolic function as a result of prolonged calcium 
ion and force transitions [36].
Using transgenic mouse models allows us to inves-
tigate genetic and phenotypic interactions in relatively a 
short period of time [58,59]. However, mice have signifi-
cantly different contractile function from humans, main-
ly due to their small size. In addition, the murine heart 
is composed mainly of alpha-myosin, while the human 
heart consists mainly of beta-myosin [53,54]. Due to 
these differences, the mouse models typically do not rep-
resent all aspects of human HCM making the direct trans-
lation of novel therapies from mouse to human incredibly 
challenging [58]. Therefore, information obtained from 
transgenic mouse models must be interpreted carefully, 
and need to be extended into larger animal models and 
eventually into humans to fully understand the genetic 
and phenotypic interactions of HCM.
HYPERTROPHIC CARDIOMYOPATHY IN 
FELINE MODELS
HCM is also the most common inherited cardiac dis-
ease in the domestic cat with a recent estimate as high 
as 1 in 7 (14.7 percent of a general population of 780 
cats screened once by echocardiogram) [60]. Approxi-
mately 57 percent of feline idiopathic cardiomyopathies 
are hypertrophic [61,62]. In 1970, a study evaluated the 
postmortem characteristics of feline cardiac disease that 
leads to congestive HF and identified feline HCM as anal-
ogous to the human form of this disease [63]. Since then, 
abundant research characterizing the pathologic, genetic, 
biochemical, and echocardiographic features of this con-
dition in cats has been published. Histopathology of fe-
line HCM is similar to that of human HCM, characterized 
by disorganized arrangement of myocytes and abnormal 
intramural coronary arterial walls (Figure 1) [64]. As in 
human HCM, clinical manifestations of feline HCM vary 
from asymptomatic to serious complications such as SD, 
HF, and thromboembolic diseases. There are, however, 
some marked differences in the clinical manifestations of 
HCM between humans and cats. In human HCM, clinical 
symptoms have a broad spectrum, and often occur as an 
asymptomatic form. The most common disease manifes-
tation of human HCM is SD in young adults and HF in 
middle-aged to elderly patients [16,17]. In contrast, fe-
line HCM is most commonly associated with congestive 
heart failure (CHF) characterized pulmonary edema and/
or pleural effusion [65]. HF. In one clinical study of cats 
with respiratory distress, more than 50 percent of those 
diagnosed with CHF had HCM [66]. This high preva-
lence of CHF in cats with HCM might be associated with 
the significant phenotypic and genotypic differences be-
ited utility and must always be interpreted in concert with 
other diagnostic tests.
There are many laboratories offering screening to 
genotype patients for known mutations associated with 
HCM. However, using single mutations to predict clini-
cal characteristics, prognosticate, or choose an appropri-
ate treatment option is unreliable for individual patients 
due to the significant heterogeneity of HCM. Currently, 
the most useful application for genetic testing is for fam-
ily screenings, particularly when individuals have rela-
tives previously diagnosed with HCM [28].
HYPERTROPHIC CARDIOMYOPATHY IN 
ANIMAL MODELS
Molecular and biochemical effects of the individual 
mutations associated with HCM have been extensively 
investigated in vitro where the function of altered pro-
teins can be directly evaluated. Proving the mutation 
results in clinical manifestation also requires studies in 
vivo with extensive pedigree analysis of HCM affected 
families or with studies using an animal model. Devel-
oping an animal HCM model provides considerable data 
in relatively short periods of time, especially regarding 
genotype and phenotype interactions as well as disease 
progression. With this purpose in mind, multiple animal 
models of HCM were developed over time [53].
HYPERTROPHIC CARDIOMYOPATHY IN 
MOUSE MODELS
Mouse models have been utilized commonly to study 
human cardiac disease, because 99 percent of human 
genes have direct murine orthologues and mice have high 
reproductive efficiency and short life spans [54]. In 1996, 
the first mouse model of HCM with a MYH7 mutation 
was created and they provided a great deal of information 
regarding the natural history of MYH7 associated HCM 
[55]. In 1999, another lineage of mice with HCM and an 
alpha-MYH mutation was created [56]. The heterozygous 
mice with this mutation had the typical features of HCM 
including LVH, but homozygous animals died shortly 
after birth. Since then, mouse models with nearly every 
known human gene mutation have been created. 
For mutations in the TNNT2 and TNNI3 genes, trans-
genic mouse models were created and morphological and 
functional changes with these mutations were investigat-
ed. For example, I79N missense mutation in the TNNT2 
was reported to be associated with higher risk of SD with-
out any significant LVH, [35] while the transgenic mice 
with this mutation developed higher contractility and 
diastolic dysfunction of the heart, potentially explaining 
the mortality especially during exercise [57]. Transgenic 
mice with TNNI3 mutation also developed LVH due to 
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TO at rest is associated with poorer outcome and higher 
risk of SD [72]. It is possible that LVOTO may be respon-
sible for elevating ventricular and atrial filling pressures, 
reducing coronary perfusion, and therefore inducing de-
velopment of subsequent ischemia and myocardial fibro-
sis. In cats with HCM, the prevalence of LVOTO is as 
high as 67 percent [69]. This is considerably higher than 
observed in human HCM patients [25]. Notably, when 
humans with HCM are assessed immediately after exer-
cise, the proportion of the HCM cases that demonstrate 
LVOTO exceeds 60 percent [15,25]. Therefore, the high 
prevalence of SAM in cats might reflect sympathetic ac-
tivation associated with a hospital visit because SAM and 
LVOTO are clearly dependent on physiological state. In-
terestingly, a few retrospective studies reported that feline 
HCM with LVOTO is associated with lower mortality 
than those without LVOTO [65,69]. The effect of LVO-
TO on morbidity and mortality in cats is thus unclear. The 
better outcomes with LVOTO in feline HCM may be sim-
ply a reflection that these cats are evaluated earlier in the 
course of disease due to their frequent development of a 
significant heart murmur. 
As in humans, feline HCM is also an inherited dis-
ease with autosomal dominant pattern and incomplete 
penetrance. In 2005, the first genetic mutation associated 
with feline HCM was identified in the MYBPC3 gene of 
Maine Coon cats [4]. Shortly after, a second mutation in 
tween humans and cats. Another possibility is that feline 
HCM is more prevalent in apparently healthy patients 
and we simply do not see these healthy cats in veterinary 
hospitals due to a lack of standardized screening proto-
cols. Supporting this hypothesis is a study that screened 
apparently healthy cats by echocardiography and ECG, 
which found HCM in 14.7 percent of the population. This 
data more closely resembles the high number of asymp-
tomatic human HCM cases [61,62].
Despite the discrepancy of clinical manifestations, 
the morphological differences of human and feline HCM 
are minimal [67,68]. This fact supports the proposal that 
HCM is basically the same disease in humans and cats 
[67]. Feline HCM is diagnosed echocardiographically 
in cats with left ventricular diastolic wall thickness that 
exceeds 6 mm (Figure 3) [69]. LVH can be asymmetric 
and it is often seen in the LV anterior wall and papillary 
muscles. Left atrial chamber size is often enlarged, but it 
is not an intrinsic feature of HCM [70]. LVOTO second-
ary to SAM is frequently identified with feline HCM as 
in human HCM (Figure 2) [62]. Systolic function (e.g., 
ejection fraction) of the left ventricle is usually normal or 
hyperdynamic, although progressive reduction in systolic 
function is noted in some HCM cats presumably second-
ary to myocardial fibrosis and/or ischemia [71]. 
Approximately 30 percent of human HCM cases are 
associated with LVOTO at rest and the presence of LVO-
Figure 3. Right parasternal short axis imaging at the level of the papillary muscle in a normal rhesus macaque (A and 
B) and a rhesus macaque with severe left ventricular hypertrophy consistent with HCM (C and D). The images are 
presented as systole (B and D) and diastole (A and C).
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vestigated in feline HCM, and found to be significantly 
elevated in HCM affected cats [81]. Notably, elevation 
of NTproBNP is also observed in cats with asymptom-
atic HCM and thus might be useful as a screening tool 
to identity high-risk patients [82]. However, as in cTnI 
and cTnT, only weak correlations between NTproBNP 
concentrations and the severity of LVH were noted. This 
contrasts with human HCM where plasma NTproBNP as 
well as cTnI and cTnI concentrations are strongly cor-
related with the severity of disease [82].
HYPERTROPHIC CARDIOMYOPATHY IN 
NON-HUMAN PRIMATE MODELS
Until recently, few case reports of SD in association 
with LVH were documented in several non-human pri-
mates such as captive chimpanzees (Pan troglodytes), 
captive western lowland gorillas (Gorilla gorilla goril-
la), and owl monkeys (aotus spp.) [83,84]. Naturally-oc-
curring LVH with a high rate of SD has been identified 
and recently reported in captive rhesus macaques. They 
present clinical and pathologic manifestations resembling 
HCM in humans [6,85]. Pedigree analysis in this cohort 
suggested that LVH in rhesus macaques is an inherited 
disease as in human and feline HCM, and is dominated 
by founder effects [7,85]. The LVH in rhesus macaques 
is often symmetric demonstrating both LV posterior and 
anterior wall thickening with occasionally hypertrophied 
papillary muscle (Figure 1) [6,85]. These changes were 
accompanied by a significant reduction of the LV cham-
ber size. Interestingly, unlike human and feline HCM, the 
histologic lesions of LVH in rhesus macaques lack the 
classical myocyte disarray, significant myocardial fibro-
sis, and intramural coronary arterial wall abnormalities. 
These histological discrepancies may imply that there 
are pathologic and genetic differences between HCM in 
humans and rhesus macaques. Nonetheless, disorganized 
myocyte architecture can be seen in regions with normal 
to mildly thickened myocardium in human HCM calling 
into question the specificity and importance of this lesion 
[86]. This pattern challenges the ideas that the degree of 
LVH is related to the degree of disorganized myocyte 
architecture, which is thought to be associated with the 
degree of clinical manifestation. In fact, as in human pa-
tients with HCM, SD remains the primary clinical mani-
festation of LVH in rhesus macaques, and this similarity 
suggests that investigating LVH in rhesus macaques may 
be worthwhile in determining the associations among the 
histological change, clinical manifestations, and genetic 
influences.
The only clinical presentation described thus far 
with LVH in rhesus macaques is SD, with the diagnosis 
of LVH made by postmortem examination. Echocardio-
graphic screening of family members also demonstrated 
the same gene but at a difference locus was also identified 
in Ragdoll cats [5]. Among these mutations, the A31P 
missense mutation in MYBPC3 gene is the most studied 
and present in approximately 30 to 40 percent of Maine 
Coon cats [30]. Young male cats are overrepresented for 
the development of HCM while female Maine Coon cats 
tend to develop HCM later in their life with milder clini-
cal signs than male respectively [73]. 
Maine Coon cats with a heterozygous A31P mutation 
status often do not develop disease or manifest reduced 
clinical severity of HCM, demonstrating low and incom-
plete penetrance (6 percent). Conversely, most homozy-
gous cats develop classical echocardiographic changes of 
HCM earlier in their life with high penetrance [19,68,74-
76]. However, recent study showed Maine Coon cats with 
the A31P MYBPC3 heterozygous mutation may have 
significantly altered cardiac function even if they do not 
develop clear morphological changes characteristic of 
HCM. In one study, Maine Coon cats heterozygous for 
the A31P mutation in MYBPC3 gene without obvious 
clinical signs had impaired diastolic function diagnosed 
based on 2D and tissue Doppler images [76]. Similar 
findings are noted in Ragdoll cats with the R820W mis-
sense mutation in MYBPC3 [77]. Overall homozygous 
mutations in MYBPC3 are associated with higher chance 
of developing physiological and functional abnormalities 
due to HCM, while heterozygous cats for either mutation 
are associated with a lower chance of developing HCM 
related changes [74,75]. To date, true longitudinal studies 
are rare in feline HCM and thus more research is needed 
to firmly determine disease penetrance and expressivity.
Findings of these major mutations in Maine Coon 
and Ragdoll cats were led by the identification of similar 
mutations in human HCM patients and feline candidate 
gene sequencing [78]. It is likely that additional genes 
will be identified in cats with HCM, and these may be 
distinct from the genes or mutations already known in 
human HCM patients. Thus far, the identified genetic 
mutations associated with HCM in cats are breed spe-
cific and represent only a small fraction of the reported 
feline HCM cases. The improved annotation of the fe-
line genome has revolutionized the ability to utilize high 
throughput technologies in the search for causative HCM 
variants in cats. With the recently published estimates of 
14.7 percent of mixed breed cats harboring subclinical 
HCM, genetic discovery is likely to increase dramatically 
in the coming years [60].
Plasma cTnI and cTnT concentrations are signifi-
cantly higher in cats with HCM compared to healthy 
cats, and even higher with CHF than without CHF due 
to HCM [79,80]. A recent study however failed to show 
correlation between changes in troponin concentration 
and the severity of feline HCM [80]. Natriuretic peptides 
including NTproBNP and NTproANP have also been in-
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pact during heart development. They discovered that the 
TNNT2 mutation in zebrafish led to a similar phenotype 
with matching myocardial hypertrophy pathways. Also, 
they observed that the embryonic hearts developed car-
diomyocyte hyperplasia. This led them to conclude that 
sarcomeric mutations can impact the cardiomyocytes 
much earlier than previously understood and that despite 
similar transcriptional responses they possess clear differ-
ences when compared to adult hearts [92]. 
Naturally occurring heritable HCM was also report-
ed in pigs, and many of the pathologic and echocardio-
graphic characteristics of HCM in pigs closely resemble 
those in humans with HCM [93-95]. Other structural and 
biochemical features in pigs are similar to those in other 
species, including increased amounts of collagen matrix, 
abnormalities in intramural coronary arteries, and de-
creased calcium ATPase activity within the LV [96-98]. 
Although the HCM-affected pig is a potential model for 
studying the pathogenesis of HCM-associated disease 
and assisting in design of therapeutic interventions, ge-
netic and heritability investigations are not fully charac-
terized and further phenotypic and genotypic studies are 
required.
HCM is a rare disease in dogs, but there are limited 
reports characterizing naturally occurring HCM in dogs 
with similar histopathologic and clinical abnormalities 
to feline and human HCM [68]. In the small number of 
reports on canine HCM some breed predilection was pro-
posed which included Rottweilers, Dalmatians, and var-
ious other breeds [68,99]. The infrequency of this con-
dition in dogs renders it impossible to draw meaningful 
conclusions at this time.
BEYOND THE GENETIC MUTATIONS
Many mutations are found to be associated with 
HCM in humans, but the molecular pathways resulting in 
the broad spectrum of HCM phenotypes remain unclear. 
Understanding these mechanisms are the cornerstone 
of developing novel HCM therapies that aim to modify 
the natural course of this disease. Several hypotheses 
explaining the development of the HCM phenotype are 
supported to varying degrees in the literature and under-
score the complex pathophysiology of this condition. The 
initially proposed hypothesis was that mutations results 
in a decreased myocardial contractility and subsequent 
LVH due to compensatory mechanisms [100]. However, 
some studies identified gain-of-function mutations with 
increased myocardial contractility, suggesting decreased 
myocardial contractility is an incomplete explanation of 
phenotypic HCM [101,102]. 
Altered myocardial calcium ion sensitivity is an-
other mechanism proposed for the various phenotypes 
of HCM. Genetic mutations in myofilament proteins in-
a high prevalence of LVH, diastolic dysfunction and mi-
tral regurgitation in rhesus macaques genetically related 
to LVH-affected individuals that died suddenly (Figure 
3). cTnI was also measured in LVH-affected and healthy 
rhesus macaques, but no significant difference was not-
ed between these groups [6]. No significant difference in 
the overall incidence of LVH between males and female 
rhesus macaques was noted, while the male rhesus ma-
caques with LVH had a higher rate of SD than female rhe-
sus macaques with LVH [20,85]. These findings may be 
influenced by social and behavioral differences between 
male and female rhesus macaques. The male macaques 
had physiological activity somewhat similar to young 
athletes who more commonly develop SD due to HCM. 
In rhesus macaques with LVH, no direct mechanisms of 
SD has been determined although it has been speculated 
to be due to ventricular arrhythmias as in human patients 
with HCM [47]. Investigation into the possible causative 
mutation and phenotypic entities of LVH in rhesus ma-
caques is underway. This new animal model of HCM is 
exciting and may represent the most direct translational 
approach to the study of human HCM. Continued pheno-
typic and genotypic investigations are essential to estab-
lish this HCM model in non-human primates.
HYPERTROPHIC CARDIOMYOPATHY IN 
OTHER SPECIES (RABBITS, FISH, PIGS, 
DOGS)
Rabbits have advantages for studying human cardio-
vascular disease due to their cardiovascular system close-
ly resembling that of humans, when compared to murine 
models [87]. This is especially true regarding calcium ion 
handling during contraction cycle and an altered calcium 
ion flux during heart failure [88]. Rabbit myosin compo-
sition more closely resembles the human heart than mu-
rine heart, which is comprised of mainly alpha myosin. 
Transgenic rabbit models with mutations in beta-MYH 
or cTnI were previously created and produced severe de-
fects including LVH and a high incidence of premature 
death [89,90].
Zebrafish are another important animal model for 
HCM. These fish are an especially important model for 
studying cardiac development, due to the external devel-
opment of the heart, enabling the assessment of cardiac 
gene function during embryologic formation. Also, ze-
brafish embryos with HCM-associated gene modifica-
tions can continue to grow for several days since they 
initially do not rely on the cardiovascular system for 
oxygen delivery. Finally, despite the simpler structure 
of the zebrafish heart compared to mammals, the essen-
tial genes responsible for heart development are largely 
conserved [91]. One research group developed a zebraf-
ish model of a TNNT2 human mutation to assess its im-
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athletes and HF in older individuals. Past research has re-
vealed a variety of genotypic and phenotypic information 
regarding HCM, which has been extensively tested and 
described through the use of animal models. Analysis of 
mouse HCM models indicate phenotypic and genotypic 
interactions that suggest specific mutations result in spe-
cific disease phenotypes. However, there are significant 
limitations to directly translate these findings into human 
HCM due to significant cardiac and hemodynamic dif-
ferences between the two species. Naturally occurring 
large animal models of HCM are necessary to bridge this 
divide. Naturally occurring HCM in cats is morpholog-
ically and histologically similar to human HCM. More-
over, similar mutations in association with HCM in some 
breeds of cats have been also identified in human HCM 
patients. These findings indicate that feline HCM re-
search may result in translational advancements and bet-
ter define the complex genotype-phenotype relationships 
that limit clinical advancements in human HCM therapy. 
Recent investigation and development of a non-human 
primate model of naturally occurring LVH in rhesus ma-
caques may also eventually shed light on the complex 
molecular pathogenesis of this condition and help to ad-
vance the diagnostic and therapeutic approaches to HCM. 
The constant evolution of new technologies, such as the 
availability of low-cost next generation sequencing and 
push towards precision medicine may also guide our un-
derstanding of genotype-phenotype relationships in this 
complex disease. The description of new animal models 
and development of novel therapeutics rooted in the mo-
lecular pathogenesis of this disease offer promise for the 
future diagnosis and management of HCM across many 
species.
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